Fate (FATE) Therapeutics had (4/8/10) announced the acquisition of Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. Terms of the purchase weren’t shared, but it adds considerable experience in muscle and pancreatic regeneration. FATE is developing small molecule and biologic drug candidates to modulate stem cell pathways to stimulate a desired outcome, such as regenerating tissue or blocking cancer growth. Read more…
Dr. Hans-Dieter Volk, Professor of Immunology and Chair of the Institute of Medical Immunology and Berlin-Brandenburg Center for Regenerative Therapies (BCRT) at Charité Universitätsmedizin in Berlinhave and Dr. Matthias von Herrath, Professor at the La Jolla Institute of Allergy and Immunology at University of San Diego been added to ISCO.OB’s Scientific Advisory Board.
Read more…
The National Institutes of Health (NIH) has allowed a contract for the dissemination of embryonic stem cell lines approved for US government funding to lapse, shuttering a key stem cell bank and doubling the price researchers pay for samples of some human embryonic stem cell (hESC) lines. Researchers hoped that stem cell research would be moving forward by leaps and bounds with the number of hESC lines approved for federal funding more than doubling since the limitations of the Bush administration were lifted in 2009. But a major stumbling block remains — getting those newly approved lines to the researchers who want to use them.
Read more…
ASTM announced the appointments of Daniel R. Salomon, M.D., Karen K. Hirschi, Ph.D., Marc Penn, M.D., Ph.D., FACC, and Mahendra Rao, M.D., Ph.D., to its newly formed scientific advisory board (SAB).
These distinguished scientists and clinicians will provide guidance in their respective areas of expertise in stem cell biology and cardiovascular disease.
Read more…
Scimitar Equity, LLC has issued a review of Aastrom Biosciences, Inc. (NASDAQ:ASTM) entitled, “New CEO Executes Bold Vision, Financing and Reverse Split with Three Phase 2 Trials Enhancing the Valuation.”
Scimitar initiates with a BUY ranking and maintains that the current momentum and share price appreciation should continue to propel ASTM to its designated valuation given substantial improvements in viability and sustainability associated with the company’s recent financing, reverse split moves, and clinical development activities.
Read more…
Fate (FATE) Therapeutics had (4/8/10) announced the acquisition of Verio Therapeutics Inc., a privately held biotechnology company based in Ottawa, Ontario, which is developing drug candidates targeting the activation of endogenous stem cells. Terms of the purchase weren’t shared, but it adds considerable experience in muscle and pancreatic regeneration. FATE is developing small molecule and biologic drug candidates to modulate stem cell pathways to stimulate a desired outcome, such as regenerating tissue or blocking cancer growth. Read more…